TD Cowen starts coverage of Centessa Pharma with 'buy'

Centessa Pharmaceuticals

07/01/2025 11:38

** TD Cowen initiates coverage of U.S.-listed shares of
Centessa Pharmaceuticals  260y.F   CNTA.O  with "buy" rating
    ** Brokerage says co's experimental drug, ORX750, is
"best-in-class" for treating excessive daytime sleepiness (EDS)
    ** EDS is a condition where a person feels very sleepy
during the day, even after getting enough sleep at night
    ** Notes ORX750 "restored wakefulness at low doses with
clean safety" in early-stage trial
    ** Brokerage says ORX750 demonstrated "higher potency and
OX2R selectivity" compared with competitors in early development
    ** OX2R, also known as orexin receptor 2, is a protein in
the brain that helps control sleep and wakefulness
    ** All 9 brokerages rate stock "buy" or higher; their median
PT is $27 - LSEG data
    ** Stock more than doubled in 2024

 (Reporting by Kamal Choudhury in Bengaluru)
 ((Kamal.Choudhury@thomsonreuters.com;))